Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection

Journal of Viral Hepatitis

Volumn 18, Issue 4, 2011, Pages

  Liu, Y ^a   Wang, C ^a   Zhong, Y ^a   Li, X ^a   Dai, J ^a   Ren, X ^a   Xu, Z ^a   Li, L ^a   Yao, Z ^a   Ji, D ^a   Wang, L ^a   Zhang, L ^a   Wong, V W S ^b   Zoulim, F ^c,d,e   Xu, Dongping ^a  

^a BEIJING 302 HOSPITAL   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c INSERM   (France)

^d UNIVERSITÉ LYON 1   (France)

^e HÔTEL DIEU   (France)

Author keywords

Drug resistance; Hepatitis B virus; Mutation; Nucleoside and nucleotide analogues

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ENTECAVIR; LAMIVUDINE; NUCLEOTIDE DERIVATIVE; TELBIVUDINE;

ADD ON THERAPY; ADULT; ARTICLE; BLOOD SAMPLING; CHINESE; COHORT ANALYSIS; FEMALE; GENE MUTATION; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VIRUS STRAIN;

ADENINE; ADULT; AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; CHINA; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; NUCLEOSIDES; PHOSPHONIC ACIDS; PYRIMIDINONES; RNA-DIRECTED DNA POLYMERASE; SEQUENCE ANALYSIS, DNA; VIRAL PROTEINS;

EID: 79952647867     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2010.01360.x     Document Type: Article

References (52)

1. Pawlotsky JM, Dusheiko G, Hatzakis A et al. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology 2008; 134: 405-415. (Pubitemid 351181309)
2. Ministry of Health of the People's Republic of China. Issued on 2008-04-21. Available at: http://www.moh.gov.cn/sofpro/cms/previewjspfile/ mohbgt/cms-0000000000000000144-tpl.jsp?requestCode=33255&CategoryID=4811. European Association for the Study of the Liver (accessed 1 April 2009).
3. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242.
4. Papatheodoridis GV, Manolakopoulos S, Dusheiko G, Archimandritis AJ. Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect Dis 2008; 8: 167-178. (Pubitemid 351249242)
5. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008; 359: 1486-1500.
6. Zoulim F, Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol 2008; 48: S2-S19.
7. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009; 137: 1593-1608.
8. Zoulim F, Buti M, Lok AS. Antiviral-resistant hepatitis B virus: can we prevent this monster from growing? J Viral Hepat 2007; 14: 29-36.
9. Allen MI, Deslauriers M, Andrews CW et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998; 27: 1670-1677. (Pubitemid 28264693)
10. Ono SK, Kato N, Shiratori Y et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 2001; 107: 449-455. (Pubitemid 32167991)
11. Delaney WEt, Yang H, Westland CE et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 2003; 77: 11833-11841. (Pubitemid 37271680)
12. Angus P, Vaughan R, Xiong S et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125: 292-297. (Pubitemid 36929407)
13. Borroto-Esoda K, Miller MD, Arterburn S. Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials. J Hepatol 2007; 47: 492-498. (Pubitemid 47334760)
14. Schildgen O, Sirma H, Funk A et al. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med 2006; 354: 1807-1812.
15. Pellicelli AM, Barbaro G, Francavilla R et al. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, openlabel study. Clin Ther 2008; 30: 317-323. (Pubitemid 351474382)
16. Qi X, Xiong S, Yang H, Miller M, Delaney WE IV. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther 2007; 12: 355-362.
17. Tenney DJ, Levine SM, Rose RE et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 2004; 48: 3498-3507. (Pubitemid 39129351)
18. Tenney DJ, Rose RE, Baldick CJ et al. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007; 51: 902-911. (Pubitemid 46355274)
19. Baldick CJ, Eggers BJ, Fang J et al. Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response. J Hepatol 2008; 48: 895-902.
20. Lai CL, Leung N, Teo EK et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005; 129: 528-536. (Pubitemid 41096641)
21. Warner N, Locarnini S. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatololgy 2008; 48: 88-98. (Pubitemid 351975534)
22. Lok AS, Zoulim F, Locarnini S et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007; 46: 254-265. (Pubitemid 47171942)
23. Brunelle MN, Jacquard AC, Pichoud C et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005; 41: 1391-1398. (Pubitemid 40770292)
24. Chinese Society of Infectious Diseases and Parasitology, Chinese Society of Hepatology. Management scheme of diagnostic and therapy criteria of viral hepatitis. Zhonghua Gan Zang Bing Za Zhi (Chinese J Hepatol) 2000; 6: 324-329.
25. Xu D, Fu J, Jin L et al. CD4+CD25+ regulatory T cells in circulation and liver actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 2006; 177: 739-747. (Pubitemid 43939189)
26. Zou Z, Xu D, Li B et al. Compartmentalization and its implication for peripheral immunologically-competent cells to the liver in patients with HBV-related acute-on-chronic liver failure. Hepatol Res 2009; 39: 1198-1207.
27. Liu Y, Zhong Z, Zou Z et al. Features and clinical implications of hepatitis B virus genotypes and mutations in basal core promoter/precore region in 507 Chinese patients with acute and chronic hepaittis B. J Clin Virol 2010; 47: 243-247.
28. Ren X, Xu Z, Liu Y et al. Hepatitis B virus genotype and basal core promoter/precore mutations are associated with hepatitis B-related acute-on-chronic liver failure without pre-existing liver cirrhosis. J Viral Hepat 2010; doi:10.1111/j.1365-2893.2009.01254.x.
29. Amini-Bavil-Olyaee S, Herbers U, Sheldon J, Luedde T, Trautwein C, Tacke F. The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positve and hepatitis B e antigen-negative hepatitis B virus strains. Hepatology 2009; 49: 1158-1165.
30. Keeffe EB, Dieterich DT, Pawlotsky JM, Benhamou Y. Chronic hepatitis B: preventing, detecting, and managing viral resistance. Clin Gastroenterol Hepatol 2008; 6: 268-274. (Pubitemid 351324881)
31. Keeffe EB, Dieterich DT, Han SH et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008; 6: 1315-1341.
32. Xu D, Zhang Z, Wang FS. SARS-associated coronavirus quasispecies in individual patients. N Engl J Med 2004; 350: 1366-1367. (Pubitemid 38375380)
33. Xu D, Zhang Z, Chu FL et al. Genetic variation of SARS coronavirus in Beijing hospital. Emerg Infect Dis 2004; 10: 789-794. (Pubitemid 38552744)
34. Xu D, Zhang Z, Jin L et al. Persistent shedding of viable SARS-CoV in urine and stool during the convalescent phase of SARS patients. Eur J Clin Microbiol Infect Dis 2005; 24: 165-171. (Pubitemid 40576662)
35. Tran N, Berne R, Chann R et al. European multicenter evaluation of high-density DNA probe arrays for detection of hepatitis B virus resistance mutations and identification of genotypes. J Clin Microbiol 2006; 44: 2792-2800. (Pubitemid 44228573)
36. Degertekin B, Hussain M, Tan J, Oberhelman K, Lod AS. Sensitivity and accuracy of an updated line probe assay (HBV DR v.3) in detecting mutations associated with hepatitis B antiviral resistance. J Hepatol 2009; 50: 42-48.
37. Hadziyannis SJ, Papatheodoridis GV. Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment. Semin Liver Dis 2006; 26: 130-141. (Pubitemid 43668255)
38. Shouval D, Lai CL, Chang TT et al. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. J Hepatol 2009; 50: 289-295.
39. Ghany MG, Doo EC. Antiviral resistance and hepatitis B therapy. Hepatology 2009; 49: S174-S184.
40. Peters MG, Hann Hw H, Martin P et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126: 91-101. (Pubitemid 38040727)
41. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007; 45: 307-313. (Pubitemid 46374587)
42. Yatsuji H, Suzuki F, Sezaki H et al. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up. J Hepatol 2008; 48: 923-931.
43. Pan XP, Li LJ, Du WB, Li MW, Cao HC, Sheng JF. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C. J Viral Hepat 2007; 14: 767-774. (Pubitemid 47561581)
44. Cha CK, Kwon HC, Cheong JY et al. Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B. J Med Virol 2009; 81: 417-424.
45. Warner N, Locarnini S, Kuiper M et al. The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. Antimicrob Agents Chemother 2007; 51: 2285-2292. (Pubitemid 47047302)
46. Yim HJ, Hussain M, Liu Y, Wong SN, Fung SK, Lok AS. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 2006; 44: 703-712. (Pubitemid 44433727)
47. Villet S, Pichoud C, Villeneuve JP, Trepo C, Zoulim F. Selection of a multiple drug-resistant hepatitis B virus strain in a liver transplanted patient. Gastroenterology 2006; 131: 1253-1261. (Pubitemid 44515103)
48. Shim JH, Suh DJ, Kim KM et al. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone. Hepatology 2009; 50: 1064-1071.
49. Santantonio T, Fasano M, Durantel S et al. Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant chronic hepatitis B. Antivir Ther 2009; 14: 557-565.
50. Inous J, Ueno Y, Wakui Y et al. Emergence of multiple drug-resistant mutants of hepatitis B virus with long-term lamivudine and adefovir bitherapy. Hepatology 2009; 50: 518A.
51. Brunelle MN, Lucifora J, Neyts J et al. In vitro activity of 2,4-Diamino-6-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants. Antimicrob Agents Chemother 2007; 51: 2240-2243.
52. Villet S, Billioud G, Pichoud C et al. In vitro characterization of viral fitness of therapy-resistant hepatitis B variants. Gastroenterology 2009; 136: 168-176.